A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 Baldwin, R. Michael , Owzar, Kouros , Zembutsu, Hitoshi ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103) Beumer, Jan H. , Owzar, Kouros , Lewis, Lionel D. , Jiang, Chen ... - - Cancer Chemother. Pharmacol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - PPP - C19808 , CALGB-100103 , CALGB-10503
Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance) Bhongsatiern, Jiraganya , Carbonetto, P. , Chua, Katherina C. ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502
Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) Chhibber, Aparna , Mefford, Joel , Stahl, Eli A. ... - - Pharmacogenomics J. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Dolan, M. Eileen , El Charif, Omar , Wheeler, Heather E. ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-90401
Whole-genome analysis informs breast cancer response to aromatase inhibition Ellis, M. J. , Ding, L. , Shen, D. , Luo, J. Q. , Suman, V. J. ... - - Nature - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - ACOSOG-Z1031
Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. Goetz, M. P. , Moyer, A. M. , Weinshilboum, R. M. , Suman, V. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Tamoxifen Pharmacogenetics of CYP2D6, CYP2C19, and SULTIA1: Long Term Follow-up of the North Central Cancer Treatment Group 89-30-52 Adjuvant Trial. Goetz, M. , Suman, V. , Ames, M. , Black, J. , Safgren, S. , Kuffel, M. ... - - Cancer Res. - 2009 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - PPP - NCCTG-89-30-52
CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of tamoxifen resistance Goetz, Matthew P. , Suman, Vera J. , Couch, Fergus J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies Goetz, Matthew P. , Sun, James X. , Suman, Vera J. , Silva, Grace O. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Goetz, Matthew P , Knox, Stacey K , Suman, Vera J , Rae, James M ... - - Breast Cancer Res. Treat. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis Harris, L. N. , Parker, J. R. , Broadwater, G. , Schulz, V. ... - - Cancer Res. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - CALGB-9342 , CALGB-9840 , CALGB-159806
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Heinrich, Michael C. , Owzar, Kouros , Corless, Christopher L. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-150105
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance) Hertz, D. L. , Owzar, K. , Halabi, S. , Kelly, W. K. , Zembutsu, H. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C90401 , CALGB-60404
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy Hertz, Daniel L. , Owzar, Kouros , Lessans, Sherrie , Wing, Claudia ... - - Clin. Cancer Res. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401
Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter? Hoskins, J. M. , Goldberg, R. M. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - N9741
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Hoskins, Janelle M , Goldberg, Richard M , Qu, Pingping ... - - J. Natl. Cancer Inst. - 2007 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - N9741
Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303 Innocenti, F. , Owzar, K. , Cox, N. J. , Evans, P. , Kubo, M. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients Innocenti, F , Jiang, C , Sibley, A B , Denning, S , Etheridge, A S ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance) Innocenti, Federico , Jiang, Chen , Sibley, Alexander B. ... - - Pharmacogenet. Genomics - 2019 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303
Genetic variation determines VEGF-A plasma levels in cancer patients Innocenti, Federico , Jiang, Chen , Sibley, Alexander B. ... - - Sci Rep - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance) Innocenti, Federico , Jiang, Chen , Sibley, Alexander ... - AACR - Cancer Res - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Innocenti, Federico , Owzar, Kouros , Cox, Nancy L. , Evans, Patrick ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303 , C151006
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation Innocenti, Federico , Owzar, Kouros , Jiang, Chen , Etheridge, Amy S. ... - - PLoS ONE - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80405
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ECC - Eur J Cancer - 2015 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80405
A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance) Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40503
Inherited genetic variation in EPHA5, FGD4 and NRDG1 and paclitaxel (P) induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101 Kroetz, D. L. , Baldwin, R. , Owzar, K. , Jiang, C. , Zembutsu, H. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C60202 , CALGB-40101
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial Lesurf, R. , Griffith, O. L. , Griffith, M. , Hundal, J. , Trani, L. ... - - Ann. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The genomics of response to neoadjuvant trastuzumab in HER2-positive breast cancer – results from the ACOSOG Z1041 (Alliance) trial Lesurf, Robert , Griffith, Malachi , Griffith, Obi , Watson, Mark A. ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer - results from the ACOSOG Z1041 (Alliance) trial Lesurf, Robert , Griffith, Obi , Griffith, Malachi , Trani, Lee ... - PCC - - 2016 Abstract - Secondary Endpoint - Primary Analysis - PPP - ACOSOG-Z1041
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance) Lewis, L. D. , Miller, A. A. , Owzar, K. , Bies, R. R. , Markova, S. ... - - Pharmacogenet Genomics - 2013 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-60805
The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors Lewis, L. D. , Rosner, G. L. , Miller, A. A. , Egorin, M. J. ... - - J. Clin. Oncol. - 2004 Abstract - Primary Endpoint - Primary Analysis - PPP - CALGB-60805
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling Li, CH , Bies, RR , Wang, Y , Sharma, MR , Karovic, S , Werk, L ... - - Clin Transl Sci - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-30203 , CALGB-30303 , CALGB-9730
Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) Li, Megan , Mulkey, Flora , Jiang, Chen , O’Neil, Bert H. ... - - Clin. Cancer Res. - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502 , CALGB-80405 , CALGB-90401 , E5103
Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC) Magbanua, M. M. , Sosa, E. V. , Eisenbud, L. E. , Scott, J. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients Magbanua, Mark Jesus M. , Sosa, Eduardo V. , Roy, Ritu ... - - Cancer Res. - 2013 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - CALGB-40502 , CALGB-40503
Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples Mahoney, D. W. , Therneau, T. M. , Anderson, S. K. , Jen, J. ... - - BMC Res Notes - 2013 Manuscript - No-Endpoint Endpoint - Primary Analysis - PPP - N9831
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741 McLeod, Howard L. , Sargent, Daniel J. , Marsh, Sharon ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - PPP - N9741
Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203 Mcleod, H. L. , Owzar, K. , Kroetz, D. L. , Innocenti, F. , Das, S. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80203
Kinetic-Pharmacodynamic Model of Chemotherapy Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel or Ixabepilone: CALGB 40502 (Alliance) Mehrotra, Shailly , Sharma, Manish R. , Gray, Elizabeth , Wu, Kehua ... - - AAPS J - 2017 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-40502
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen Moyer, Ann M , Suman, Vera J , Weinshilboum, Richard M ... - - Pharmacogenomics - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - N89-30-52
Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147) Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-N0147
A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) Patel, Jai N. , Jiang, Chen , Owzar, Kouros , Hertz, Daniel L. ... - AACR - Cancer Res. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-90401
Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology) Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - N0147
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance) Rashkin, Sara R. , Chua, Katherina C. , Ho, Carol , Mulkey, Flora ... - - Clin. Pharmacol. Ther. - 2019 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-40502
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen Schroth, Werner , Goetz, Matthew P. , Hamann, Ute ... - - JAMA - 2009 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - N89-30-52
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Sharma, Manish R , Mehrotra, Shailly , Gray, Elizabeth , Wu, Kehua ... - - J Clin Pharmacol - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502
Genome-Wide Meta-Analyses Identifies Novel Taxane-Induced Peripheral Neuropathy Associated Loci Sucheston-Campbell, L E , Clay-Gilmour, A I , Barlow, W E , Budd, G T ... - - Pharmacogenet. Genomics - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101 , S0221
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance) Wang, X. , Owzar, K. , Gupta, P. , Larson, R. A. , Mulkey, F. ... - - Clin Pharm Therapeut - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-10105
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance) Wang, Xiaofeng , Owzar, Kouros , Gupta, Pankaj , Larson, Richard A ... - - Br J Clin Pharmacol - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-10105
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy Wheeler, Heather E. , Gamazon, Eric R. , Wing, Claudia ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer Wolpin, Brian M. , Rizzato, Cosmeri , Kraft, Peter ... - - Nat. Genet. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C80303
Tumor and germline markers for gemcitabine sensitivity in pancreatic cancer Yee, S. , Collisson, E. , Gysin, S. , Owzar, K. , Jiang, C. ... - PGRN - - 2009 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer Yuan, Chen , Renfro, Lindsay , Ambadwar, Pratibha B. , Ou, Fang-Shu ... - - Cancer Causes Control - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - N9741
